To evaluate the efficacy of once-daily oral HRS-7535 in reducing hemoglobin A1c levels in patients with type 2 diabetes inadequately controlled with metformin, particularly focusing on the demographic characteristics of the population.
Key Findings:
HRS-7535 reduced hemoglobin A1c levels significantly compared to placebo, with reductions of 1.19% to 1.82% across different doses (p < 0.05).
49% to 63% of patients on HRS-7535 achieved hemoglobin A1c levels below 7.0%, compared to 15% in the placebo group (p < 0.05).
Rescue antihyperglycemic therapy was required in 3% to 8% of patients receiving HRS-7535, compared to 31% in the placebo group (p < 0.05).
Gastrointestinal adverse events were common, with nausea occurring in 8% to 34% of patients on HRS-7535.
Interpretation:
The study demonstrated statistically significant reductions in hemoglobin A1c with HRS-7535 in the studied population, suggesting potential benefits for clinical practice, although caution is advised in generalizing results to other populations.
Limitations:
The trial duration of 16 weeks may not fully capture long-term glycemic responses.
The study population had a mean body mass index of 26.7, which may not represent higher BMI populations in Western countries, potentially affecting generalizability.
No formal adjustment for multiplicity was applied, necessitating cautious interpretation of secondary endpoints.
Conclusion:
HRS-7535 shows promise in lowering A1c levels in type 2 diabetes patients, but further studies are needed to confirm efficacy and safety, particularly in diverse populations.
